Abstract

Abstract The purpose of the present study was to develop a peptide for treatment of multiple sclerosis (MS). We have tested the effect of a novel antiinflammatory peptide (KGHYAERVG, termed IIIM1) on experimental autoimmune encephalitis (EAE), an animal model of MS. Our findings demonstrate significant reduction in neurological score following oral administration of IIIM1, as compared to the control groups received the vehicle (saline). Structural studies revealed that the entire peptide is required for activity. The peptide caused significant reduction in IL17, interferon gamma and IL12 production by isolated splenocytes and concomitant elevation of antiinflammatory cytokines. IIIM1 elevated T regulatory cells (Tregs, CD4+CD25+FoxP3+) in brain and spleen of EAE mice. Similar proliferative effect was observed in isolated human and mouse Tregs in vitro. Stimulation of Tregs by IIIM1 caused production of a new peptide termed RA1 present in Oryza Sativa Japonica group. This Japanese rice peptide ameliorated neurological symptoms in the EAE model. Similar beneficial effect was observed upon oral administration of an extract of Japanese rice. In conclusion, oral treatment with IIIM1 ameliorates EAE symptoms via stimulation of Tregs to proliferate and produce RA1 which reduces EAE symptoms. These findings may explain the relatively low prevalence of MS in Japan and other Japanese rice-eating populations. (This work was supported in part by The Israel Science Foundation grant 747/05).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call